Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31473884 | 0.84 | ALDH1A1 (0.61) | TYMSALDH1A1EGFRSMN1; SMN2MAPT | |
| SCHEMBL8981 | 0.84 | ALDH1A1 (0.61) | TYMSALDH1A1EGFRSMN1; SMN2MAPT | |
| SCHEMBL12540 | 0.79 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2MAPTPOLBHPGD | |
| SCHEMBL4483413 | 0.79 | NOS1 (0.44) | ALDH1A1RAB9AMAPK1NOS1METAP2 | |
| SCHEMBL1170673 | 0.79 | PDPK1 (0.51) | ALDH1A1SMN1; SMN2KDM4ERAB9ANPC1 | |
| SCHEMBL25457211 | 0.79 | RAB9A (0.53) | ALDH1A1SMN1; SMN2MAPTPOLBHPGD | |
| SCHEMBL14474327 | 0.78 | CASP3 (0.45) | TYMSALDH1A1EGFRMAPTHPGD | |
| SCHEMBL11816656 | 0.78 | EGFR (0.44) | ALDH1A1EGFRSMN1; SMN2POLBHPGD | |
| SCHEMBL12052868 | 0.78 | POLB (0.51) | ALDH1A1SMN1; SMN2MAPTPOLBHPGD | |
| SCHEMBL1405835 | 0.76 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2MAPTPOLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119425419-A | Metal-organic framework composite membrane for helium and methane mixed gas separation and preparation method and application thereof | 苏州大学 | 2025-02-14 | — | — | CN | claimed |
| EP-1976829-A2 | N-(6-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 2008-10-08 | — | — | EP | claimed |
| US-20070265262-A1 | N-(6-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. | 2007-11-15 | — | — | US | claimed |
| WO-2007070556-A2 | N-(6-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 2007-06-21 | — | — | WO | claimed |
| US-20260125378-A2 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| EP-4702021-A1 | COMPOUNDS CAPABLE OF MODULATING GPR65 | Pathios Therapeutics Limited (GB) | 2026-03-04 | — | — | EP | disclosed |
| EP-4288426-B1 | QUINOXALINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| EP-4658650-A1 | HETEROCYCLIC COMPOUNDS | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20250353846-A1 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2025-11-20 | — | — | US | disclosed |
| CN-120424484-A | Scratch-resistant high-transparency polycarbonate with self-repairing function and preparation method thereof | 青岛国恩科技股份有限公司 | 2025-08-05 | — | — | CN | disclosed |
| CN-119425419-A | Metal-organic framework composite membrane for helium and methane mixed gas separation and preparation method and application thereof | 苏州大学 | 2025-02-14 | — | — | CN | disclosed |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | SGX PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | SGX PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| EP-1685124-A1 | SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LTD. (GB) | 2006-08-02 | — | — | EP | disclosed |
| WO-2006015123-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060030583-A1 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | US | disclosed |
| WO-2005047279-A1 | SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2005-05-26 | — | — | WO | disclosed |
| EP-1509497-A1 | CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES | Amgen Inc. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003099776-A1 | CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES | AMGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125378-A2 | Heterocyclic Compounds | NFATC1, CD4, MALT1 | TYMS 398/4885ALDH1A1 2837/4885EGFR 875/4885 |
| US-20070265262-A1 | N-(6-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | ZC3HAV1, HAVCR2, ZC3HAV1L | TYMS 761/4885ALDH1A1 4167/4885EGFR 3991/4885 |
| US-20250353846-A1 | Heterocyclic Compounds | NFATC1, CD4, ACIN1 | TYMS 255/4885ALDH1A1 1006/4885EGFR 1358/4885 |
| US-20060030583-A1 | Pyrrolo-pyridine kinase modulators | MAP3K20, MAP4K2, MAP3K19 | TYMS 731/4885ALDH1A1 4474/4885EGFR 877/4885 |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | MAP3K20, MAP4K2, MAP3K6 | TYMS 1488/4885ALDH1A1 4281/4885EGFR 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.